Veradermics posts positive Phase 2 data for VDPHL01 in female pattern hair loss, paving the way for a pivotal readout
MANE has more than doubled off its 52-week low of $32.
Summary
VDPHL01 hit its Phase 2 endpoints in female pattern hair loss, delivering robust hair count increases and high patient-reported improvement. The data boost confidence ahead of the pivotal Phase 2/3 readout in 1H 2027 and support a potential first-in-class oral approval.
Key Events · Product Development and Regulatory · MANE
-
Phase 2 Hit in Female Hair Loss
At Month 6, VDPHL01 4.5mg once or twice daily achieved mean non-vellus hair count increases of 22.7 and 23.3 hairs/cm², with 88.9% and 90.0% of patients reporting 'improved' or 'much improved' hair coverage.
-
Clean Safety Profile
No treatment-related serious adverse events or cardiac adverse events of special interest were observed; the most common side effects were hypertrichosis (21.4%) and peripheral edema (7.1%).
-
Rapid Onset of Effect
As early as Month 2—the earliest measured time point—63.2% of participants reported improvement in hair coverage.
-
Pivotal Catalyst in 1H 2027
Topline data from the registration-directed Phase 2/3 Study 306 in female pattern hair loss is expected in the first half of 2027; male confirmatory Phase 3 data (Study 304) is due in 2H 2026.
Analysis · MANE · Life Sciences
Veradermics announced positive topline results from its Phase 2 'Study 207' evaluating VDPHL01 in women with pattern hair loss. The drug demonstrated rapid, consistent hair growth alongside a favorable safety profile, positioning it as a potential first FDA-approved oral treatment for a market of 30 million U.S. women. These results de-risk the ongoing Phase 2/3 registration trial (Study 306) and reinforce the broader VDPHL01 franchise, which already has positive male data. With a strong cash position extending runway into 2030, the company is well-funded to execute its pivotal program.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1070 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MANE was trading at $119.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $32.00 to $131.24. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.